NEWS | Nov. 15, 2021

JPM CBRN Medical Announces RPP in Support of Vaccine Acceleration Program

By Press Release

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear (CBRN) Defense’s (JPEO-CBRND) Joint Project Manager for CBRN Medical (JPM CBRN Medical), in collaboration with the JPEO-CBRND’s Joint Project Lead for CBRN Defense Enabling Biotechnologies (JPL CBRND EB), and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA), released a request for prototype proposal (RPP) on November 10, 2021, soliciting offers for mRNA vaccine development through December 13, 2021. These offers will include mRNA vaccine design, non-clinical testing, and clinical testing against priority biological threats.   

In July 2021, the JPM CBRN Medical held an mRNA vaccine development and delivery industry day to gauge interest in new vaccine technologies from academia, industry, and nonprofits. The RPP is a result of the discussions held with these CBRN defense stakeholders, and will support the JPM CBRN Medical’s upcoming Vaccine Acceleration by Modular Progression (VAMP) program.

The VAMP program intends to use lessons learned from COVID-19 vaccine efforts to shorten future emergency response timelines and develop interim capabilities, approved or authorized by the U.S. Food and Drug Administration (FDA). “The success of the COVID-19 vaccines have shown us that investment in mRNA vaccine technology holds great promise to enable development of a framework and potentially strategic reserves to cover broader threat families, faster,” said Col. Ryan Eckmeier, the Joint Project Manager for CBRN Medical.

To join the solicitation, or read the full text of the solicitation, interested companies need to be members of the Medical CBRN Defense Consortium (MCDC). Visit the MCDC website to learn more about the consortium, how to join the consortium, and how to participate in the RPP.
 
About the JPM CBRN Medical: The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability. To learn more about the JPM CBRN Medical, visit https://www.jpeocbrnd.osd.mil/coronavirus or follow JPEO-CBRND on social media at @JPEOCBRND. 
About the JPEO-CBRND: The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) protects the Joint Force by providing medical countermeasures and defense equipment against chemical, biological, radiological and nuclear (CBRN) threats. JPEO-CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. JPEO-CBRND facilitates the rapid response, advanced development, manufacturing and acquisition of medical solutions, such as vaccines, therapeutics, and diagnostics, to combat CBRN and emerging threats such as COVID-19. To learn more about JPEO-CBRND’s COVID-19 response, visit https://www.jpeocbrnd.osd.mil/coronavirus or follow JPEO-CBRND on social media at @JPEOCBRND.

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.  

 

 


JPEO-CBRND Public Affairs Office

The JPEO-CBRND Communications Affairs Network coordinates and responds to all Public Affairs needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.